https://www.biopharmawatch.com/news/ALC/aravind-alcon-global-centre-coimbatore BiopharmaWatch en 2026-07-24T13:12:00.000Z Aravind Eye Care System und Alcon eröffnen in Coimbatore, Indien, ein globales Kompetenzzentrum für die Ausbildung im Bereich Netzhautmedizin https://www.biopharmawatch.com/news/HYFT/mindwalk-reveals-reefIQ-ai-drug-discovery BiopharmaWatch en 2026-07-24T13:10:00.000Z A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed https://www.biopharmawatch.com/news/SGRY/surgery-partners-agreement-sale-idaho-falls-facilities BiopharmaWatch en 2026-07-24T13:00:00.000Z Surgery Partners Announces Entry Into Agreement to Sell Ownership Interests in Idaho Falls Facilities to Intermountain Health; Reaffirms Guidance, Excluding Impact of Transaction https://www.biopharmawatch.com/news/AMIX/autonomix-medical-renal-nerve-sensing-study BiopharmaWatch en 2026-07-24T12:47:00.000Z Autonomix Medical Demonstrates Renal Nerve Sensing and Neural Activity Change in Preclinical Study https://www.biopharmawatch.com/news/VIR/vir-biotechnology-cfo-transition BiopharmaWatch en 2026-07-24T12:30:00.000Z Vir Biotechnology Announces Chief Financial Officer Transition https://www.biopharmawatch.com/news/RDGT/ridgetech-leadership-zhejiang-biomedical-association BiopharmaWatch en 2026-07-24T12:30:00.000Z Ridgetech Strengthens Pharmaceutical Ecosystem Leadership with Vice-President Role in Zhejiang Biomedical Association https://www.biopharmawatch.com/news/IMMP/immutep-abstract-esmo-congress-2026 BiopharmaWatch en 2026-07-24T12:00:00.000Z Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026 https://www.biopharmawatch.com/news/OGN/organon-vtama-phase-3-data-improvements-eczema BiopharmaWatch en 2026-07-24T12:00:00.000Z New Analysis of Phase 3 Pooled Data for Organon’s VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1 https://www.biopharmawatch.com/news/ESLA/estrella-immunopharma-starlight-1-trial-update BiopharmaWatch en 2026-07-24T12:00:00.000Z Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-chmp-opinion-obicetrapib BiopharmaWatch en 2026-07-24T12:00:00.000Z NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) https://www.biopharmawatch.com/news/PHGE/biomx-zorronet-european-collaborations BiopharmaWatch en 2026-07-24T11:45:00.000Z BiomX Subsidiary Zorronet Expands European Presence Through Two Strategic Collaborations in Europe https://www.biopharmawatch.com/news/HCA/hca-healthcare-reports-q2-2026-results BiopharmaWatch en 2026-07-24T11:30:00.000Z HCA Healthcare Reports Second Quarter 2026 Results https://www.biopharmawatch.com/news/CGC/canopy-growth-q1-2027-financial-results-report BiopharmaWatch en 2026-07-24T11:30:00.000Z Canopy Growth to Report First Quarter Fiscal 2027 Financial Results on August 7, 2026 https://www.biopharmawatch.com/news/ZVRA/zevra-therapeutics-arimoclomol-npc-regulatory-update BiopharmaWatch en 2026-07-24T11:30:00.000Z Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union https://www.biopharmawatch.com/news/RADX/radiopharm-theranostics-us4-1-million-offering BiopharmaWatch en 2026-07-24T11:15:00.000Z Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan https://www.biopharmawatch.com/news/QDEL/quidelortho-report-q2-2026-financial-results BiopharmaWatch en 2026-07-24T11:00:00.000Z QuidelOrtho to Report Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-second-quarter-2026-results BiopharmaWatch en 2026-07-24T10:50:00.000Z ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET https://www.biopharmawatch.com/news/MRK/merck-alimatravir-access-plans-hiv-prevention BiopharmaWatch en 2026-07-24T10:45:00.000Z Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development https://www.biopharmawatch.com/news/ALC/aravind-alcon-global-centre-excellence-retina-training BiopharmaWatch en 2026-07-24T10:37:00.000Z Aravind Eye Care System and Alcon Launch Global Centre of Excellence for Retina Training in Coimbatore, India https://www.biopharmawatch.com/news/MNKD/mannkind-announces-50-million-private-placement BiopharmaWatch en 2026-07-24T10:35:00.000Z MannKind Announces $50 Million Private Placement https://www.biopharmawatch.com/news/MNKD/mannkind-furoscix-readyflow-fda-approval BiopharmaWatch en 2026-07-24T10:30:00.000Z MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease https://www.biopharmawatch.com/news/GILD/chmp-recommends-gilead-trodelvy-keytruda-tnbc BiopharmaWatch en 2026-07-24T10:26:00.000Z CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer https://www.biopharmawatch.com/news/SER/serina-therapeutics-btig-conference-2026 BiopharmaWatch en 2026-07-24T10:00:00.000Z Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference https://www.biopharmawatch.com/news/SNY/sanofi-discontinues-amlitelimab-atopic-dermatitis BiopharmaWatch en 2026-07-24T05:30:00.000Z Press Release: Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews https://www.biopharmawatch.com/news/YDES/yd-bio-eg-biomed-collaboration-success BiopharmaWatch en 2026-07-24T03:29:17.000Z YD Bio 攜手愛立基生醫圓滿完成 2026 亞洲生技大展展出，展示眼科、腫瘤診斷與臨床服務領域創新成果 https://www.biopharmawatch.com/news/TLX/tlx400-tx-encouraging-disease-control-mtc BiopharmaWatch en 2026-07-23T23:49:33.000Z EJNMMI Research: TLX400-Tx Shows Encouraging Disease Control in Medullary Thyroid Cancer https://www.biopharmawatch.com/news/CPHI/china-pharma-holdings-5-million-offering BiopharmaWatch en 2026-07-23T22:49:00.000Z China Pharma Holdings, Inc. Announces Closing of $5.0 Million Registered Direct Offering https://www.biopharmawatch.com/news/HSCS/heartsciences-fiscal-2026-annual-report BiopharmaWatch en 2026-07-23T21:15:00.000Z HeartSciences Files Its Fiscal 2026 Annual Report on Form 10-K https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-q2-2026-results-announcement BiopharmaWatch en 2026-07-23T21:15:00.000Z Rapid Micro Biosystems to Announce Second Quarter 2026 Financial Results on August 7, 2026 https://www.biopharmawatch.com/news/KRYS/krystal-biotech-q2-2026-financial-results BiopharmaWatch en 2026-07-23T21:00:00.000Z Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026 https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-merger-update-cash-dividend BiopharmaWatch en 2026-07-23T20:33:00.152Z VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience https://www.biopharmawatch.com/news/ALGN/align-technology-innovations-invisalign-treatment-planning BiopharmaWatch en 2026-07-23T20:30:00.000Z Align Technology Announces New Innovations to Advance Invisalign® Treatment Planning and Enhance Patient Engagement Through Its Integrated Align™ Digital Platform https://www.biopharmawatch.com/news/CVRX/cvrx-second-quarter-2026-results-conference-call BiopharmaWatch en 2026-07-23T20:30:00.000Z CVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026 https://www.biopharmawatch.com/news/PRME/prime-medicine-fda-clearance-pm577a-wilson-disease BiopharmaWatch en 2026-07-23T20:18:32.766Z Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease https://www.biopharmawatch.com/news/IMVT/immunovant-financial-results-q1-2026-business-update BiopharmaWatch en 2026-07-23T20:18:03.631Z Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026 https://www.biopharmawatch.com/news/ABVX/abivax-strengthens-commercial-capabilities-leadership-appointments BiopharmaWatch en 2026-07-23T20:17:50.073Z Abivax Strengthens Commercial Capabilities With Strategic Leadership Appointments https://www.biopharmawatch.com/news/ROIV/roivant-financial-results-business-update-august-2026 BiopharmaWatch en 2026-07-23T20:17:28.055Z Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026 https://www.biopharmawatch.com/news/GEHC/ge-healthcare-cfo-transition-q2-2026-results BiopharmaWatch en 2026-07-23T20:15:00.000Z GE HealthCare announces CFO transition; reports preliminary second quarter 2026 financial results and reaffirms guidance reflecting business momentum https://www.biopharmawatch.com/news/EW/edwards-lifesciences-q2-results-2026 BiopharmaWatch en 2026-07-23T20:15:00.000Z Edwards Lifesciences Reports Second Quarter Results https://www.biopharmawatch.com/news/PBYI/puma-biotechnology-conference-call-q2-2026 BiopharmaWatch en 2026-07-23T20:10:00.000Z Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/AORT/artivion-second-quarter-2026-financial-results BiopharmaWatch en 2026-07-23T20:10:00.000Z Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ABBV/genmab-abbvie-phase-3-epcore-dlbcl-1-trial-update BiopharmaWatch en 2026-07-23T20:05:00.000Z Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) https://www.biopharmawatch.com/news/SMMT/summit-therapeutics-q2-2026-results BiopharmaWatch en 2026-07-23T20:05:00.000Z Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026 https://www.biopharmawatch.com/news/THC/tenet-reports-strong-q2-2026-results BiopharmaWatch en 2026-07-23T20:05:00.000Z Tenet Reports Strong Second Quarter 2026 Results; Raises 2026 Financial Outlook https://www.biopharmawatch.com/news/HYPR/hyperfine-announces-q2-2026-financial-results BiopharmaWatch en 2026-07-23T20:05:00.000Z Hyperfine, Inc. to Announce Second Quarter 2026 Financial Results on August 6, 2026 https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-leadership-hiring-promotions BiopharmaWatch en 2026-07-23T20:05:00.000Z Neurocrine Biosciences Announces Key Leadership Hiring, Promotions https://www.biopharmawatch.com/news/HYFT/mindwalk-showcases-reefiq-ai-drug-discovery-amd BiopharmaWatch en 2026-07-23T20:02:00.000Z MindWalk Showcases ReefIQ™ for AI Drug Discovery at AMD Advancing AI https://www.biopharmawatch.com/news/MGNX/macrogenics-phase-1-study-update-mgc026 BiopharmaWatch en 2026-07-23T20:01:00.000Z MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026 https://www.biopharmawatch.com/news/HTFL/heartflow-second-quarter-2026-financial-results BiopharmaWatch en 2026-07-23T20:01:00.000Z Heartflow to Report Second Quarter 2026 Financial Results on August 13, 2026 https://www.biopharmawatch.com/news/ATRC/atricure-reports-q2-2026-financial-results BiopharmaWatch en 2026-07-23T20:01:00.000Z AtriCure Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/DCTH/delcath-systems-second-quarter-2026-earnings-call BiopharmaWatch en 2026-07-23T20:01:00.000Z Delcath Systems to Host Second Quarter 2026 Earnings Call https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-q2-2026-results-call BiopharmaWatch en 2026-07-23T20:01:00.000Z Kiniksa Pharmaceuticals to Report Second Quarter 2026 Financial Results on July 28, 2026 https://www.biopharmawatch.com/news/ABBV/epcore-dlbcl-1-trial-results-abbv BiopharmaWatch en 2026-07-23T20:00:00.000Z Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) https://www.biopharmawatch.com/news/CYTK/cytokinetics-second-quarter-results-august-2026 BiopharmaWatch en 2026-07-23T20:00:00.000Z Cytokinetics to Announce Second Quarter Results on August 6, 2026 https://www.biopharmawatch.com/news/GMAB/genmab-abbvie-phase-3-epcore-dlbcl-1-trial-clarification BiopharmaWatch en 2026-07-23T20:00:00.000Z Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) https://www.biopharmawatch.com/news/BMRN/megan-bull-career-impact-biopharma BiopharmaWatch en 2026-07-23T18:12:04.000Z Megan Bull’s Childhood Empathy Fuels a Career of Impact https://www.biopharmawatch.com/news/EVO/evotec-selects-navan-global-expense-management BiopharmaWatch en 2026-07-23T16:59:00.000Z Resumen: Evotec elige a Navan para unificar la gestión mundial de los pagos y viáticos https://www.biopharmawatch.com/news/EVO/evotec-selects-navan-global-travel-expense-management BiopharmaWatch en 2026-07-23T16:59:00.000Z Riassunto: Evotec sceglie Navan per unificare a livello globale viaggi, pagamenti e gestione delle spese https://www.biopharmawatch.com/news/EVO/evotec-selects-navan-global-travel-management BiopharmaWatch en 2026-07-23T16:59:00.000Z Samenvatting: Evotec selecteert Navan om het globale beheer van reizen, betalingen en uitgaven een te maken https://www.biopharmawatch.com/news/EVO/evotec-selects-navan-for-expense-management BiopharmaWatch en 2026-07-23T16:58:00.000Z Evotec entscheidet sich für Navan zur Vereinheitlichung des Managements von Reisespesen und Ausgaben https://www.biopharmawatch.com/news/EVO/evotec-navan-global-travel-management BiopharmaWatch en 2026-07-23T16:58:00.000Z Evotec choisit Navan pour unifier la gestion mondiale des voyages, des paiements et des notes de frais https://www.biopharmawatch.com/news/OLMA/costa-bingo-pros-cons-austria BiopharmaWatch en 2026-07-23T16:32:49.000Z Costa Bingo Pros And Cons For Austria: Games, Bonuses, And Payout Speed https://www.biopharmawatch.com/news/OPK/opko-health-report-q2-2026-results BiopharmaWatch en 2026-07-23T16:30:00.000Z OPKO Health to Report Second Quarter 2026 Financial Results on July 27, 2026 https://www.biopharmawatch.com/news/OKYO/okyo-pharma-director-share-purchase BiopharmaWatch en 2026-07-23T16:00:00.000Z OKYO Pharma Announces Purchase of Shares by Director https://www.biopharmawatch.com/news/OMDA/omada-health-q2-2026-results-conference-call BiopharmaWatch en 2026-07-23T15:27:00.000Z UPDATE - Omada Health to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 6, 2026 https://www.biopharmawatch.com/news/MENS/jyong-biotech-global-bph-market-opportunity BiopharmaWatch en 2026-07-23T14:52:00.000Z Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships https://www.biopharmawatch.com/news/INDV/indivior-report-q2-2026-financial-results-webcast BiopharmaWatch en 2026-07-23T14:00:00.000Z Indivior to Report Second Quarter 2026 Financial Results and Host Webcast https://www.biopharmawatch.com/news/HSTM/healthstream-second-quarter-2026-earnings-call BiopharmaWatch en 2026-07-23T13:25:00.000Z HealthStream to Host Second Quarter 2026 Earnings Conference Call https://www.biopharmawatch.com/news/IMNN/imunon-imnn-001-data-aacr-conference BiopharmaWatch en 2026-07-23T13:25:00.000Z IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development https://www.biopharmawatch.com/news/QDEL/beyond-fentanyl-drug-crisis-changing BiopharmaWatch en 2026-07-23T13:21:00.000Z Beyond Fentanyl: How the Drug Crisis Is Changing https://www.biopharmawatch.com/news/LGVN/deborah-ascheim-elected-longeveron-board BiopharmaWatch en 2026-07-23T13:15:00.000Z Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors https://www.biopharmawatch.com/news/OMDA/omada-health-q2-2026-results-conference-call BiopharmaWatch en 2026-07-23T13:05:44.995Z Omada Health to Announce First Quarter 2026 Financial Results and Host Conference Call on August 6, 2026 https://www.biopharmawatch.com/news/OM/outset-medical-q2-2026-financial-results BiopharmaWatch en 2026-07-23T13:05:31.212Z Outset Medical to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 https://www.biopharmawatch.com/news/HYFT/mindwalk-holdings-revenue-growth-recurring-contracts BiopharmaWatch en 2026-07-23T13:05:00.000Z An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers https://www.biopharmawatch.com/news/MYGN/myriad-genetics-q2-2026-financial-results BiopharmaWatch en 2026-07-23T13:05:00.000Z Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026 https://www.biopharmawatch.com/news/NVO/crux-novo-nordisk-access-wegovy-obesity-medications BiopharmaWatch en 2026-07-23T13:01:00.000Z Crux Collaborates with Novo Nordisk to Offer Access to Wegovy® and Other Obesity Management Medications https://www.biopharmawatch.com/news/NVCT/nuvectis-ciprocopan-approval-china-pnh BiopharmaWatch en 2026-07-23T13:00:00.000Z Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors https://www.biopharmawatch.com/news/BIO/bio-rad-second-quarter-2026-financial-results BiopharmaWatch en 2026-07-23T13:00:00.000Z Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026 https://www.biopharmawatch.com/news/SXTC/china-sxt-pharmaceuticals-9-million-offering BiopharmaWatch en 2026-07-23T12:45:00.000Z China SXT Pharmaceuticals Inc. Announces $9 Million Registered Direct Offering https://www.biopharmawatch.com/news/AIDX/2020-biolabs-standstill-agreement-streeterville-capital BiopharmaWatch en 2026-07-23T12:31:00.000Z 20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock https://www.biopharmawatch.com/news/LNTH/lantheus-second-quarter-2026-earnings-call BiopharmaWatch en 2026-07-23T12:30:00.000Z Lantheus to Host Second Quarter 2026 Earnings Conference Call and Webcast on August 6, 2026, at 8:00 a.m. Eastern Time https://www.biopharmawatch.com/news/ICUI/icu-medical-q2-2026-earnings-call BiopharmaWatch en 2026-07-23T12:30:00.000Z ICU Medical Announces Time of Second Quarter 2026 Earnings Conference Call https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-fda-510k-submission BiopharmaWatch en 2026-07-23T12:30:00.000Z Intelligent Bio Solutions Achieves Key Milestone Ahead of Planned FDA 510(k) Submission, Advancing Toward Planned U.S. Market Entry https://www.biopharmawatch.com/news/FEED/envue-medical-navigation-platform-deployment BiopharmaWatch en 2026-07-23T12:30:00.000Z ENvue Medical Deploys Additional Navigation Platform with Existing Customer, A Leading North Texas Medical Center https://www.biopharmawatch.com/news/WVE/wave-life-sciences-q2-2026-financial-results-webcast BiopharmaWatch en 2026-07-23T12:30:00.000Z Wave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026 https://www.biopharmawatch.com/news/HALO/halozyme-report-q2-2026-results BiopharmaWatch en 2026-07-23T12:30:00.000Z Halozyme to Report Second Quarter 2026 Financial and Operating Results https://www.biopharmawatch.com/news/ALMR/alzpath-alamar-strategic-agreement-clinical-diagnostics BiopharmaWatch en 2026-07-23T12:30:00.000Z ALZpath Broadens Strategic Agreement with Alamar Biosciences to Advance Clinical Diagnostics for Alzheimer's Disease https://www.biopharmawatch.com/news/BBLG/bone-biologics-mid-year-update-2026 BiopharmaWatch en 2026-07-23T12:08:58.131Z Bone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities https://www.biopharmawatch.com/news/IMDX/imdex-graftassure-assay-kidney-graft-saving-drug BiopharmaWatch en 2026-07-23T12:08:41.675Z iMDx GraftAssure Assay Guides Use of Potentially Kidney-Graft-Saving Drug in New Lancet Group Publication https://www.biopharmawatch.com/news/APYX/apyx-medical-q2-2026-financial-results-release BiopharmaWatch en 2026-07-23T12:08:26.382Z Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026 https://www.biopharmawatch.com/news/LTRN/lantern-pharma-uspto-patent-allowance-ltrn BiopharmaWatch en 2026-07-23T12:01:00.000Z Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers https://www.biopharmawatch.com/news/ARDX/ardelyx-second-quarter-2026-financial-results BiopharmaWatch en 2026-07-23T12:01:00.000Z Ardelyx to Report Second Quarter 2026 Financial Results on August 6, 2026 https://www.biopharmawatch.com/news/ARDT/ardent-health-ambient-ai-milestone BiopharmaWatch en 2026-07-23T12:00:00.000Z Ardent Health surpasses 1 million patient encounters supported by ambient AI https://www.biopharmawatch.com/news/ESTA/establishment-labs-q2-2026-financial-results-announcement BiopharmaWatch en 2026-07-23T12:00:00.000Z Establishment Labs® to Announce Second Quarter 2026 Financial Results on August 6 https://www.biopharmawatch.com/news/A/agilent-eu-approval-pd-l1-ihc-22c3 BiopharmaWatch en 2026-07-23T12:00:00.000Z Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma https://www.biopharmawatch.com/news/RVTY/revvity-t-spot-tb-automated-platform-development BiopharmaWatch en 2026-07-23T12:00:00.000Z Revvity Announces Development of High-Throughput T-SPOT.TB Automated Platform for Clinical Labs https://www.biopharmawatch.com/news/CNTN/canton-strategic-holdings-sale-gravitas-life-sciences BiopharmaWatch en 2026-07-23T12:00:00.000Z Canton Strategic Holdings, Inc. Announces Sale of Gravitas Life Sciences, LLC https://www.biopharmawatch.com/news/CYRX/cryoport-second-quarter-2026-financial-results BiopharmaWatch en 2026-07-23T12:00:00.000Z Cryoport to Report Second Quarter 2026 Financial Results on August 6, 2026 https://www.biopharmawatch.com/news/EHC/encompass-health-dividend-increase-2026 BiopharmaWatch en 2026-07-23T12:00:00.000Z Encompass Health increases and declares dividend on common stock https://www.biopharmawatch.com/news/YDES/yd-bio-eg-biomed-bio-asia-taiwan-2026-exhibition BiopharmaWatch en 2026-07-23T12:00:00.000Z YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services https://www.biopharmawatch.com/news/HCWB/hcw-biologics-tetravalent-t-cell-engager-clinical-trials-2027 BiopharmaWatch en 2026-07-23T12:00:00.000Z HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical Trials in First Half 2027 https://www.biopharmawatch.com/news/PETS/petmeds-sale-leaseback-headquarters-distribution-center BiopharmaWatch en 2026-07-23T12:00:00.000Z PetMeds Announces Proposed Sale-Leaseback of Headquarters and Distribution Center Buildings for $37 Million https://www.biopharmawatch.com/news/COLL/collegium-report-second-quarter-2026-results BiopharmaWatch en 2026-07-23T12:00:00.000Z Collegium to Report Second Quarter 2026 Financial Results on August 6, 2026 https://www.biopharmawatch.com/news/IKT/inhibikase-therapeutics-fda-orphan-drug-designation-ikt-001 BiopharmaWatch en 2026-07-23T12:00:00.000Z Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH https://www.biopharmawatch.com/news/XERS/xeris-biopharma-q2-2026-financial-results BiopharmaWatch en 2026-07-23T11:30:00.000Z Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026 https://www.biopharmawatch.com/news/VSTM/verastem-oncology-q2-2026-financial-results BiopharmaWatch en 2026-07-23T11:30:00.000Z Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026 https://www.biopharmawatch.com/news/NVCT/ciprocopan-approval-china-pnh-treatment BiopharmaWatch en 2026-07-23T11:30:00.000Z Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors https://www.biopharmawatch.com/news/AMIX/autonomix-medical-us-patent-precision-neuromodulation BiopharmaWatch en 2026-07-23T11:30:00.000Z Autonomix Medical Secures New U.S. Patent Strengthening Next-Generation Precision Neuromodulation Platform https://www.biopharmawatch.com/news/BKD/brookdale-senior-living-most-loved-workplace-certification BiopharmaWatch en 2026-07-23T11:17:00.000Z Brookdale Senior Living Earns Certified Most Loved Workplace® Recognition https://www.biopharmawatch.com/news/ACB/safari-flower-eu-gmp-certification-aurora-cannabis BiopharmaWatch en 2026-07-23T11:05:00.000Z Safari Flower Company, a Wholly Owned Subsidiary of Aurora Cannabis, Receives EU-GMP Certification at Niagara Facility https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-dorothy-gemmell-board-appointment BiopharmaWatch en 2026-07-23T11:05:00.000Z Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors https://www.biopharmawatch.com/news/NVCR/novocure-reports-second-quarter-2026-results BiopharmaWatch en 2026-07-23T11:00:00.000Z Novocure Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/INSM/insmed-second-quarter-2026-financial-results-call BiopharmaWatch en 2026-07-23T11:00:00.000Z Insmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026 https://www.biopharmawatch.com/news/SHC/sotera-health-second-quarter-2026-earnings-release BiopharmaWatch en 2026-07-23T11:00:00.000Z Sotera Health Announces Second-Quarter 2026 Earnings Release Date https://www.biopharmawatch.com/news/TLRY/tilray-launches-zonna-thc-pouches BiopharmaWatch en 2026-07-23T11:00:00.000Z Tilray Brands Launches ZONNA, Introducing New THC Pouches for Cannabis Consumers https://www.biopharmawatch.com/news/OKYO/okyo-pharma-ceo-share-purchase BiopharmaWatch en 2026-07-23T11:00:00.000Z OKYO Pharma Announces Purchase of Shares by Chief Executive Officer https://www.biopharmawatch.com/news/VRXA/veraxa-biotech-appoints-christoph-erkel-cso BiopharmaWatch en 2026-07-23T11:00:00.000Z VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolio https://www.biopharmawatch.com/news/DGX/quest-diagnostics-q2-2026-financial-results BiopharmaWatch en 2026-07-23T10:45:00.000Z Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026 https://www.biopharmawatch.com/news/TFX/teleflex-second-quarter-2026-earnings-call BiopharmaWatch en 2026-07-23T10:30:00.000Z Teleflex Announces Second Quarter 2026 Earnings Conference Call Information https://www.biopharmawatch.com/news/UTHR/united-therapeutics-appoints-victor-dzau-board BiopharmaWatch en 2026-07-23T10:30:00.000Z United Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of Directors https://www.biopharmawatch.com/news/AVAH/aveanna-second-quarter-2026-earnings-release BiopharmaWatch en 2026-07-23T10:30:00.000Z Aveanna Announces Second Quarter 2026 Earnings Release Date and Conference Call https://www.biopharmawatch.com/news/NEUP/scancell-neuphoria-merger-agreement-financing BiopharmaWatch en 2026-07-23T10:11:00.000Z Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing https://www.biopharmawatch.com/news/ONC/beone-medicines-us-manufacturing-expansion BiopharmaWatch en 2026-07-23T10:00:00.000Z BeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance Innovative Cancer Medicines https://www.biopharmawatch.com/news/WST/west-pharmaceutical-second-quarter-2026-results BiopharmaWatch en 2026-07-23T10:00:00.000Z West Reports Second-Quarter 2026 Results https://www.biopharmawatch.com/news/TDOC/teladoc-one-new-model-virtual-care BiopharmaWatch en 2026-07-23T10:00:00.000Z Teladoc Health introduces a virtual care practice built around the person, shaping a new era of connected care https://www.biopharmawatch.com/news/EVO/evotec-selects-navan-travel-expense-management BiopharmaWatch en 2026-07-23T07:00:00.000Z Evotec Selects Navan to Unify Global Travel, Payments, and Expense Management https://www.biopharmawatch.com/news/IPHA/innate-pharma-bladder-cancer-panel-btig-conference BiopharmaWatch en 2026-07-23T05:00:00.000Z Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference https://www.biopharmawatch.com/news/ARGX/argenx-half-year-2026-financial-results-update BiopharmaWatch en 2026-07-23T05:00:00.000Z argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update https://www.biopharmawatch.com/news/CUVL/clinuvel-strategic-reorganisation-us-markets BiopharmaWatch en 2026-07-23T04:10:00.000Z CLINUVEL implements strategic reorganisation to refocus on U.S. markets https://www.biopharmawatch.com/news/LLY/lilly-retatrutide-phase-3-trials-results BiopharmaWatch en 2026-07-23T00:00:00.000Z Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from... https://www.biopharmawatch.com/news/JNJ/tecvayli-talvey-phase-3-results-multiple-myeloma BiopharmaWatch en 2026-07-23T00:00:00.000Z TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma Johnson & Johnson (NYSE: JNJ), a worldwide leader in multiple myeloma therapies, today announced positive topline results from the three-arm... https://www.biopharmawatch.com/news/DXCM/dexcom-first-participant-fda-tempo-pilot-program BiopharmaWatch en 2026-07-22T21:15:00.000Z Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program https://www.biopharmawatch.com/news/EHTH/ehealth-second-quarter-2026-earnings-call BiopharmaWatch en 2026-07-22T21:15:00.000Z eHealth, Inc. to Hold Second Quarter 2026 Earnings Call on August 4 at 5:00 p.m. Eastern Time https://www.biopharmawatch.com/news/SUPN/supernus-pharmaceuticals-q2-2026-results-conference-call BiopharmaWatch en 2026-07-22T21:05:00.000Z Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026 https://www.biopharmawatch.com/news/HYFT/mindwalk-holdings-fiscal-2026-results BiopharmaWatch en 2026-07-22T20:54:00.000Z MindWalk Holdings Corp. Reports Fiscal 2026 Results: Revenue Up 46% as the Company Completes Its Pivot to Bio-Native AI Infrastructure https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-avoe-oncology-casdatifan-tivozanib BiopharmaWatch en 2026-07-22T20:35:00.000Z Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients https://www.biopharmawatch.com/news/EXEL/exelixis-second-quarter-2026-results-release BiopharmaWatch en 2026-07-22T20:30:00.000Z Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026 https://www.biopharmawatch.com/news/PFE/fda-priority-review-pfizer-talzenna-xtandi BiopharmaWatch en 2026-07-22T20:30:00.000Z FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer https://www.biopharmawatch.com/news/RCUS/arcus-summit-collaboration-kidney-cancer-trial BiopharmaWatch en 2026-07-22T20:30:00.000Z Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer https://www.biopharmawatch.com/news/SER/serina-therapeutics-appoints-farrell-simon-board BiopharmaWatch en 2026-07-22T20:30:00.000Z Serina Therapeutics Appoints Farrell Simon to its Board of Directors https://www.biopharmawatch.com/news/MEDP/medpace-holdings-q2-2026-results BiopharmaWatch en 2026-07-22T20:15:00.000Z Medpace Holdings, Inc. Reports Second Quarter 2026 Results https://www.biopharmawatch.com/news/CYH/community-health-systems-q2-2026-results BiopharmaWatch en 2026-07-22T20:15:00.000Z Community Health Systems, Inc. Announces Second Quarter Ended June 30, 2026 Results https://www.biopharmawatch.com/news/MOH/molina-healthcare-q2-2026-financial-results BiopharmaWatch en 2026-07-22T20:15:00.000Z Molina Healthcare Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/OSUR/orasure-second-quarter-2026-financial-results-call BiopharmaWatch en 2026-07-22T20:10:00.000Z OraSure to Announce Second Quarter 2026 Financial Results and Host Earnings Call on August 5th https://www.biopharmawatch.com/news/BTMD/biote-schedules-q2-2026-financial-results-release BiopharmaWatch en 2026-07-22T20:05:00.000Z Biote Schedules Second Quarter 2026 Financial Results Release and Conference Call https://www.biopharmawatch.com/news/VIR/vir-biotechnology-conference-call-q2-2026 BiopharmaWatch en 2026-07-22T20:05:00.000Z Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/RVMD/revolution-medicines-daraxonrasib-fda-review BiopharmaWatch en 2026-07-22T20:05:00.000Z Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-q2-2026-financial-results BiopharmaWatch en 2026-07-22T20:05:00.000Z Cytek Biosciences to Report Second Quarter 2026 Financial Results on August 5, 2026 https://www.biopharmawatch.com/news/ACB/aurora-cannabis-first-quarter-2027-conference-call BiopharmaWatch en 2026-07-22T20:05:00.000Z Aurora Cannabis to Host First Quarter 2027 Investor Conference Call https://www.biopharmawatch.com/news/AVNS/avanos-medical-stockholders-approve-acquisition BiopharmaWatch en 2026-07-22T20:05:00.000Z Avanos Medical, Inc. Stockholders Approve Acquisition by American Industrial Partners https://www.biopharmawatch.com/news/NUVB/nuvation-bio-q2-2026-financial-results-update BiopharmaWatch en 2026-07-22T20:05:00.000Z Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026 https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-07-22T20:05:00.000Z Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026 https://www.biopharmawatch.com/news/SGHT/sight-sciences-q2-2026-financial-results-report BiopharmaWatch en 2026-07-22T20:05:00.000Z Sight Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026 https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-earnings-call-august-2026 BiopharmaWatch en 2026-07-22T20:02:00.000Z Maravai LifeSciences To Host Earnings Conference Call on Thursday, August 6, 2026 https://www.biopharmawatch.com/news/VSTM/verastem-target-d-202-trial-vs-7375-nsclc BiopharmaWatch en 2026-07-22T20:01:00.000Z Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer https://www.biopharmawatch.com/news/TKNO/teknova-q2-2026-financial-results-report BiopharmaWatch en 2026-07-22T20:01:00.000Z Teknova to Report Second Quarter 2026 Financial Results on August 5, 2026 https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-q2-2026-financial-results BiopharmaWatch en 2026-07-22T20:01:00.000Z Emergent BioSolutions to Report Second Quarter 2026 Financial Results on August 5, 2026 https://www.biopharmawatch.com/news/GUTS/fractyl-health-investor-events-2026 BiopharmaWatch en 2026-07-22T20:01:00.000Z Fractyl Health to Participate in Upcoming Investor Events https://www.biopharmawatch.com/news/CARL/carlsmed-q2-2026-financial-results-report BiopharmaWatch en 2026-07-22T20:01:00.000Z Carlsmed Inc. to Report Second Quarter 2026 Financial Results on August 5, 2026 https://www.biopharmawatch.com/news/PRLD/precision-degrader-antibody-conjugates-targeted-therapeutics BiopharmaWatch en 2026-07-22T19:14:00.000Z Precision degrader-antibody conjugates (pDACs) with a SMARCA2/4 dual payload as targeted therapeutics for acute myeloid leukemia https://www.biopharmawatch.com/news/PEN/thunder-study-penumbra-thunderbolt-stroke-care BiopharmaWatch en 2026-07-22T18:35:00.000Z THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care https://www.biopharmawatch.com/news/IMRX/david-caouette-joins-immuneering BiopharmaWatch en 2026-07-22T18:23:21.000Z David Caouette https://www.biopharmawatch.com/news/CHRS/coherus-oncology-q2-2026-financial-results BiopharmaWatch en 2026-07-22T17:36:00.000Z Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026 https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-renmark-roadshow-participation BiopharmaWatch en 2026-07-22T16:31:15.000Z Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series https://www.biopharmawatch.com/news/VALN/valneva-first-half-2026-financial-results BiopharmaWatch en 2026-07-22T15:45:00.000Z Valneva to Report First Half 2026 Consolidated Financial Results on August 13, 2026 https://www.biopharmawatch.com/news/LLY/lilly-second-quarter-2026-financial-results BiopharmaWatch en 2026-07-22T14:00:00.000Z Lilly confirms date and conference call for second-quarter 2026 financial results announcement https://www.biopharmawatch.com/news/OKYO/okyo-pharma-share-purchase-development-officer BiopharmaWatch en 2026-07-22T14:00:00.000Z OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director https://www.biopharmawatch.com/news/CPHI/china-pharma-pricing-5-million-offering BiopharmaWatch en 2026-07-22T13:25:00.000Z China Pharma Announces Pricing of $5 Million Registered Direct Offering